Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance.

Kim SN, Doo AR, Park JY, Choo HJ, Shim I, Park JJ, Chae Y, Lee B, Lee H, Park HJ.

Brain Res. 2014 Jan 28;1544:33-44. doi: 10.1016/j.brainres.2013.11.028. Epub 2013 Dec 7.

PMID:
24321617
[PubMed - in process]
2.

Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.

Doo AR, Kim SN, Hahm DH, Yoo HH, Park JY, Lee H, Jeon S, Kim J, Park SU, Park HJ.

BMC Complement Altern Med. 2014 Mar 20;14:107. doi: 10.1186/1472-6882-14-107.

PMID:
24650244
[PubMed - in process]
Free PMC Article
3.

Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.

Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA.

Neurobiol Dis. 2011 Jun;42(3):327-40. doi: 10.1016/j.nbd.2011.01.024. Epub 2011 Feb 19.

PMID:
21310234
[PubMed - indexed for MEDLINE]
4.

BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.

Spinnewyn B, Mautino G, Marin JG, Rocher MN, Grandoulier AS, Ferrandis E, Auguet M, Chabrier PE.

Neuropharmacology. 2011 Mar;60(4):692-700. doi: 10.1016/j.neuropharm.2010.11.019. Epub 2010 Dec 1.

PMID:
21129389
[PubMed - indexed for MEDLINE]
5.

Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.

Iderberg H, Rylander D, Bimpisidis Z, Cenci MA.

Exp Neurol. 2013 Dec;250:116-24. doi: 10.1016/j.expneurol.2013.09.003. Epub 2013 Sep 10.

PMID:
24029003
[PubMed - indexed for MEDLINE]
6.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
[PubMed - indexed for MEDLINE]
Free Article
7.
8.

L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.

Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA.

J Neurochem. 2010 Mar;112(6):1465-76. doi: 10.1111/j.1471-4159.2009.06556.x. Epub 2009 Dec 24.

PMID:
20050978
[PubMed - indexed for MEDLINE]
9.

L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

Winkler C, Kirik D, Björklund A, Cenci MA.

Neurobiol Dis. 2002 Jul;10(2):165-86.

PMID:
12127155
[PubMed - indexed for MEDLINE]
10.

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.

Fox SH, Chuang R, Brotchie JM.

Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Review.

PMID:
18772047
[PubMed - indexed for MEDLINE]
11.

Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.

Ravenscroft P, Chalon S, Brotchie JM, Crossman AR.

Exp Neurol. 2004 Jan;185(1):36-46.

PMID:
14697317
[PubMed - indexed for MEDLINE]
12.

Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.

Barnum CJ, Eskow KL, Dupre K, Blandino P Jr, Deak T, Bishop C.

Neuroscience. 2008 Sep 22;156(1):30-41. doi: 10.1016/j.neuroscience.2008.07.016. Epub 2008 Jul 12.

PMID:
18687386
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.

Pavón N, Martín AB, Mendialdua A, Moratalla R.

Biol Psychiatry. 2006 Jan 1;59(1):64-74. Epub 2005 Sep 1.

PMID:
16139809
[PubMed - indexed for MEDLINE]
14.

Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.

Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA.

J Neurochem. 2007 Apr;101(2):483-97. Epub 2007 Jan 15.

PMID:
17359492
[PubMed - indexed for MEDLINE]
15.

Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.

Lundblad M, Usiello A, Carta M, Håkansson K, Fisone G, Cenci MA.

Exp Neurol. 2005 Jul;194(1):66-75.

PMID:
15899244
[PubMed - indexed for MEDLINE]
16.

Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.

Kobylecki C, Crossman AR, Ravenscroft P.

Exp Neurol. 2013 Sep;247:476-84. doi: 10.1016/j.expneurol.2013.01.019. Epub 2013 Jan 27.

PMID:
23360800
[PubMed - indexed for MEDLINE]
17.

Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.

Chagniel L, Robitaille C, Lebel M, Cyr M.

Neurobiol Dis. 2012 Jan;45(1):645-55. doi: 10.1016/j.nbd.2011.10.011. Epub 2011 Oct 19.

PMID:
22037042
[PubMed - indexed for MEDLINE]
18.

Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.

Quintana A, Sgambato-Faure V, Savasta M.

Neurobiol Dis. 2012 Dec;48(3):379-90. doi: 10.1016/j.nbd.2012.06.009. Epub 2012 Jun 30.

PMID:
22759925
[PubMed - indexed for MEDLINE]
19.

A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.

Lundblad M, Picconi B, Lindgren H, Cenci MA.

Neurobiol Dis. 2004 Jun;16(1):110-23.

PMID:
15207268
[PubMed - indexed for MEDLINE]
20.

The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.

Thornton E, Hassall MM, Corrigan F, Vink R.

Parkinsonism Relat Disord. 2014 May;20(5):508-13. doi: 10.1016/j.parkreldis.2014.02.008. Epub 2014 Feb 20.

PMID:
24637127
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk